Medscheme released updated MEDICINE EXCLUSION LIST APRIL 2023

By HEOR Staff Writer

April 10, 2023

Some items listed as REQUIRING PRE-AUTHORISATION:

  • Forxiga (Dapagliflozin)
  • Byetta (Exenatide)
  • Janumet (Metformin/Sitagliptin)
  • Onglyza (Saxagliptin)
  • Januvia (Sitagliptin)
  • Galvus (Vildagliptin) + including Metformin combinations
  • Liptruzet (Atorvastatin/Ezetimibe)
  • Ezetrol (Ezetimibe)
  • Inegy(Ezetimibe/Simvastatin)

Details regarding the EXCLUDED ITEMS:

  • Trulicity (Dulaglutide)
  • Jardiance (Empagliflozin)
  • Xultophy (Insulin Degludec and Liraglutide)
  • Soliqua (Insulin Glargine and Lixisenatide)
  • Victoza (Liraglutide)
  • Synjardy (Metformin and Empagliflozin)
  • Ozempic (Semaglutide)
Reference url

Recent Posts

Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision

By João L. Carapinha

February 13, 2026

Exposing Prescription Drug Pricing Flaws Prescription drug pricing in the US is riddled with inefficiencies, as revealed in this JAMA interview published online on Febru...
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

By João L. Carapinha

February 12, 2026

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...
South Africa Health Reform: Navigating Innovations and Challenges for 2026

By João L. Carapinha

February 10, 2026

South Africa Health Reform: Contrasts in 2026 Public Health Agenda South Africa health reform defines the 2026 public health landscape as a mix of breakthroughs like HIV prevention injections and AI-driven TB diagnos...